Creation of Side-to-Side Compression Anastomosis Using the Magnetic Anastomosis System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-18

Study Completion Date

2024-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an operationally seamless, open-label, multicenter study enrolling up to 50 subjects with obesity and with or without type 2 diabetes at up to 5 study centers across Canada and Europe who will undergo sleeve gastrectomy (revision or de novo) with side-to-side anastomosis duodeno-ileostomy using the MAGNET System and will be followed for 12 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System in Mexico

NCT07085741

Obesity Type 2 Diabetes

ACTIVE_NOT_RECRUITING NA

MagDI Diversion Feasibility Study

NCT05692518

Type 2 Diabetes Obesity

COMPLETED NA

Magnetic Gastro-Ileal or Gastro-Jejunal Diversion Study ("MGI/MGJ Study")

NCT06073457

Obesity Type 2 Diabetes

RECRUITING NA

GT Metabolic Magnet System in Adults With Gastrointestinal Disorders

NCT07317076

Gastric Outlet Obstruction Small Bowel Obstruction Superior Mesenteric Artery Syndrome

RECRUITING NA

Magnetic Duodeno-Ileal Chile Study

NCT06613724

Obesity Type 2 Diabetes Mellitus (T2DM)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The MAGNET study is an operationally seamless, 2-stage, open-label, multicenter study enrolling up to 50 subjects at up to 5 study centers across Canada and Europe as follows:

* Stage 1 first-in-human (FIH) and proof-of-concept with 5 subjects; and
* Stage 2 feasibility with 45 subjects.

There will be a pause after completing enrollment in Stage 1 to allow completion of Day 30 and evaluation of safety by the independent Data Safety Monitoring Committee (DSMB). The DSMB will confirm whether the study can advance to Stage 2. All subjects in Stage 1 and 2 will be followed for 12 months.

Study Procedure: Side-to-side anastomosis duodeno-ileostomy diversion procedure using the MAGNET System

Study Population: Adults (18 to 65 years of age, inclusive) with obesity (BMI 30-50) who meet one of the following criteria: (1) have type 2 diabetes mellitus (T2DM) or experienced weight regain following previous sleeve gastrectomy; (2) have T2DM without previous sleeve gastrectomy; or (3) are candidates for a laparoscopic single anastomosis duodenal-ileal bypass with sleeve (SADI-S) procedure and have BMI ≥ 40.

Follow-up: Each subject will return for 6 follow-up visits at Day 14, 30, 60, 90, 180, 270 and 360 (end of study).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

An operationally seamless, 2-stage, open-label, multicenter study enrolling up to 50 subjects at up to 5 study centers across Canada and Europe:

* Stage 1 first-in-human (FIH) and proof-of-concept with 5 subjects; and
* Stage 2 feasibility with 45 subjects.

There will be a pause after completing enrollment in Stage 1 to allow completion of Day 30 and evaluation of safety by the independent Data Safety Monitoring Committee (DSMB). The DSMB will confirm whether the study can advance to Stage 2. All subjects in Stage 1 and 2 will be followed for 12 months.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Side-to-side anastomosis duodeno-ileostomy diversion

Group Type EXPERIMENTAL

Side-to-side anastomosis duodeno-ileostomy diversion procedure

Intervention Type DEVICE

Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Side-to-side anastomosis duodeno-ileostomy diversion procedure

Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions Magnetic Anastomosis System (The MAGNET System) to Achieve Duodeno-Ileostomy Diversion.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

The MAGNET System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-65 years of age, inclusive, at the time of informed consent
* BMI 30-50, inclusive with either:

* Previous-sleeve gastrectomy (\> 12 months) with either T2DM (defined as HbA1c \> 6.5%) or weight regain; or
* T2DM without previous gastrectomy; or
* Undergoing laparoscopic single anastomosis duodenal-ileal bypass with sleeve (SADI-S) where duodeno-ileostomy is performed side to side with the MAGNET System and BMI \> 40
* Agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for 1 year
* If a child-bearing female, subject must commit to not becoming pregnant and agree to use contraception for 1 year
* Willing and able to comply with protocol requirements

Exclusion Criteria

* Type 1 diabetes
* Use of injectable insulin
* Uncontrolled T2DM
* Uncontrolled hypertension, dyslipidemia or sleep apnea
* Prior intestinal, colonic or duodenal surgery, other than bariatric
* Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contra- indicate the procedure, including scarring and abnormal anatomy
* Refractory gastro-esophageal reflux disease (GERD)
* Barrett's disease
* Helicobacter pylori positive and/or active ulcer disease
* Large hiatal hernia
* Inflammatory bowel or colonic diverticulitis disease
* Any anomaly precluding orogastric access by gastroscope and catheters, and manipulation techniques
* Implantable pacemaker or defibrillator
* Psychiatric disorders, except well-controlled depression with medication for \>6mo, or history of substance abuse
* Woman who is either pregnant or breast feeding
* Woman of childbearing potential who does not agree to use an effective method of contraception
* Any comorbidity or current status of subject's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the subject medically unfit for the procedure. This includes any conditions for which endoscopic or laparoscopic surgery would be contraindicated, and any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the magnets.
* Unhealed ulcers, bleeding lesions, tumor or any other lesion at target magnet deployment site
* Expected need for MR imaging within the first 2 months after the procedure
* Any anomaly preventing/contraindicating laparoscopic access and general laparoscopic procedures
* Had surgical or interventional procedure within 30 days prior to procedure
* Any scheduled surgical or interventional procedure planned within 30 days post-procedure
* Any stroke/TIA within 6 months prior to consent
* Requires chronic anticoagulation therapy (except aspirin)
* Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure
* Unable to comply with the follow-up schedule and assessments
* Recent tobacco or nicotine product cessation within \< 3 months prior to informed consent
* Known allergies to the device components or contrast media
* Limited life expectancy due to terminal disease
* Currently participating in another clinical research study with an investigational drug or medical device
* A positive COVID-19 test prior to the study procedure
* Any condition that, in the investigator's opinion, may preclude completion of follow-up assessments through Day 360 (e.g., a medical condition that may increase the risk associated with study participation or may interfere with interpretation of study results, inability to adhere to the visit schedule, or poor compliance with treatment regimen)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No